CN112220816A - Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids - Google Patents

Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids Download PDF

Info

Publication number
CN112220816A
CN112220816A CN202011165759.7A CN202011165759A CN112220816A CN 112220816 A CN112220816 A CN 112220816A CN 202011165759 A CN202011165759 A CN 202011165759A CN 112220816 A CN112220816 A CN 112220816A
Authority
CN
China
Prior art keywords
percent
emulsion
preventing
glycerol
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011165759.7A
Other languages
Chinese (zh)
Inventor
殷传江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202011165759.7A priority Critical patent/CN112220816A/en
Publication of CN112220816A publication Critical patent/CN112220816A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses an emulsion for preventing and treating hemorrhoids, a preparation method thereof and wet paper towels for preventing and treating hemorrhoids, wherein the emulsion for preventing and treating hemorrhoids comprises the following components in percentage by weight: 3 to 6 percent of egg oil, 0.5 to 1.0 percent of polyglycerol-10 laurate, 0.1 to 0.5 percent of tocopherol acetate, 0.05 to 0.2 percent of o-cymene-5-alcohol, 0.05 to 0.25 percent of triclosan, 0.1 to 0.2 percent of butylated hydroxytoluene, 0.1 to 0.5 percent of borneol, 0.001 to 0.01 percent of muscone, 0.1 to 0.3 percent of xanthan gum, 5.0 to 8.0 percent of glycerol, 1.0 to 4.0 percent of glycerol glucoside, 0.5 to 2.5 percent of alum, 0.5 to 2.5 percent of zinc gluconate, 0.5 to 2.5 percent of tranexamic acid, 3.0 to 8.0 percent of pearl hydrolysate, 0.02 to 0.1 percent of disodium EDTA, 0.1 to 0.4 percent of phenoxyethanol, 0.1 to 0.2 percent of methylparaben, and the balance of water; the hemorrhoid prevention and treatment wet tissue is obtained by soaking the folded non-woven fabric in the hemorrhoid prevention and treatment emulsion, filtering the residual emulsion, bagging and sealing. The invention can effectively prevent and treat hemorrhoids and reduce the pain of patients, and is convenient to use and carry.

Description

Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids
Technical Field
The invention relates to the technical field of hemorrhoid prevention and treatment, and particularly relates to an emulsion for preventing and treating hemorrhoid, a preparation method thereof and wet paper towels for preventing and treating hemorrhoid.
Background
Hemorrhoids are common anorectal diseases and bring great pain to patients. The general survey data show that the incidence rate of anorectal diseases is 59.1%, hemorrhoids account for 87.25% of all anorectal diseases, and internal hemorrhoids are the most common hemorrhoids and account for 52.19% of all anorectal diseases. Both men and women can get ill, the incidence rate of women is 67%, and the incidence rate of men is 53.9%; the disease can be developed at any age, and among them, people of 20-40 years old are more common and gradually worsen with the increase of age, so that the theory of 'ten hemorrhoids' exists. Hemorrhoids or Piles are named by scholars in English, American and other countries, the former named after bleeding as a clinical characteristic, and the latter named after the appearance of Hemorrhoids looks like a ball, which generally refers to internal and external Hemorrhoids.
When the force is continuously applied during defecation, the pressure in the veins is repeatedly increased, and the veins are enlarged. Women often suffer from hemorrhoids during pregnancy due to pelvic veins being compressed, which prevents blood circulation, and many obese people also suffer from hemorrhoids. If hemorrhoids are suffered, the swollen and twisted vein wall in the anus becomes very thin, so that the anus is easy to break when defecating. Internal hemorrhoids are hemorrhoids that grow at the beginning of the anal canal and if the dilated veins are located further down, almost at the anal orifice, the varicose veins are called external hemorrhoids. External hemorrhoids sometimes prolapse or protrude from the anal canal orifice. However, this situation only occurs when defecation occurs, after which it retracts to its original position. Thrombosis can occur in both internal and external hemorrhoids. When a thrombus occurs, blood in the hemorrhoid coagulates into a mass, causing pain.
At present, the means for treating the primary and secondary hemorrhoids are usually hip bath or topical application (various hemorrhoid suppositories and ointments), the curative effect is insufficient, and patients are easy to depend on partial medicines (such as enema); the treatment means for treating the third and fourth-stage hemorrhoids is usually surgical excision, and patients need to bear great pain and the postoperative rehabilitation is slow.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the emulsion for preventing and treating the hemorrhoids, which can effectively prevent and treat the hemorrhoids, reduce the pain of patients and is convenient to use and carry, the preparation method thereof and the wet paper towel for preventing and treating the hemorrhoids.
The technical scheme adopted by the invention for solving the technical problems is as follows:
in a first aspect, the invention provides an emulsion for preventing and treating hemorrhoids, which comprises the following components in percentage by weight:
3 to 6 percent of egg oil, 0.5 to 1.0 percent of polyglycerol-10 laurate, 0.1 to 0.5 percent of tocopherol acetate, 0.05 to 0.2 percent of o-cymene-5-alcohol, 0.05 to 0.25 percent of triclosan, 0.1 to 0.2 percent of butylated hydroxytoluene, 0.1 to 0.5 percent of borneol, 0.001 to 0.01 percent of muscone, 0.1 to 0.3 percent of xanthan gum, 5.0 to 8.0 percent of glycerol, 1.0 to 4.0 percent of glycerol glucoside, 0.5 to 2.5 percent of alum, 0.5 to 2.5 percent of zinc gluconate, 0.5 to 2.5 percent of tranexamic acid, 3.0 to 8.0 percent of pearl hydrolysate, 0.02 to 0.1 percent of disodium EDTA, 0.1 to 0.4 percent of phenoxyethanol, 0.1 to 0.2 percent of methylparaben, and the balance of water.
Further, the components are preferably as follows by weight percentage: 3% of egg oil, 1.0% of polyglycerol-10 laurate, 0.1% of tocopherol acetate, 0.2% of o-cymene-5-ol, 0.2% of triclosan, 0.2% of butylated hydroxytoluene, 0.2% of borneol, 0.01% of musk ketone, 0.3% of xanthan gum, 5.0% of glycerol, 4.0% of glycerol glucoside, 2% of alum, 2% of zinc gluconate, 2% of tranexamic acid, 8.0% of hydrolyzed pearl liquid, 0.1% of EDTA disodium, 0.2% of phenoxyethanol, 0.1% of methylparaben and the balance of water.
Further, the components are preferably as follows by weight percentage: 5% of egg oil, 0.8% of polyglycerol-10 laurate, 0.5% of tocopherol acetate, 0.1% of o-cymene-5-alcohol, 0.1% of triclosan, 0.1% of butylated hydroxytoluene, 0.3% of borneol, 0.005% of musk ketone, 0.2% of xanthan gum, 6% of glycerol, 2% of glycerol glucoside, 1.2% of alum, 1.5% of zinc gluconate, 1% of tranexamic acid, 5.0% of hydrolyzed pearl liquid, 0.06% of EDTA disodium, 0.3% of phenoxyethanol, 0.2% of methylparaben and the balance of water.
Further, the components are preferably as follows by weight percentage: 6% of egg oil, 0.5% of polyglycerol-10 laurate, 0.2% of tocopherol acetate, 0.1% of o-cymene-5-ol, 0.15% of triclosan, 0.1% of butylated hydroxytoluene, 0.1% of borneol, 0.005% of musk ketone, 0.1% of xanthan gum, 5.0% of glycerol, 2% of glycerol glucoside, 1% of alum, 0.2% of zinc gluconate, 0.5% of tranexamic acid, 3.0% of pearl hydrolysate, 0.05% of EDTA disodium, 0.1% of phenoxyethanol, 0.1% of methylparaben and the balance of water.
In a first aspect, the invention provides a preparation method of the emulsion for preventing and treating hemorrhoids, which comprises the following steps:
s1, oil phase preparation: sequentially adding the egg oil, polyglycerol-10 lauric acid, tocopherol acetate, o-cymene-5-alcohol, triclosan, butylated hydroxytoluene, borneol and muscone into an oil phase pot, heating to 80-85 ℃, and uniformly stirring;
s2, preparing a water phase: adding xanthan gum, glycerol glucoside, Alumen, zinc gluconate, tranexamic acid, hydrolyzed Margarita liquid, phenoxyethanol, methyl hydroxybenzoate and water into water phase pot, heating to 80-85 deg.C, and stirring;
s3, emulsification: and (3) adding the raw materials in the water phase pot and the oil phase pot into an emulsifying pot, uniformly stirring, cooling to 40-45 ℃, filtering and discharging to obtain a finished product.
Further, in S3, the raw materials in the emulsifying pot are stirred uniformly, homogenized for 5 minutes, and then cooled.
In a third aspect, the invention provides a hemorrhoid prevention and treatment wet tissue, which is obtained by soaking a folded non-woven fabric in the hemorrhoid prevention and treatment emulsion, filtering out the residual emulsion, bagging and sealing.
The invention has the beneficial effects that:
1. alum and zinc gluconate have the functions of astringency, detumescence, hemostasis and antisepsis; borneol has the functions of diminishing inflammation and relieving pain, is an essential medicine for treating inflammation of hemorrhoid and has an antibacterial effect; the pearl is a product for detoxifying, dissipating blood stasis, promoting granulation and stopping bleeding, and has the functions of antisepsis and relieving pain when being applied locally; muscone is used for clearing heat, relieving convulsion, treating carbuncle, furuncle, skin ulcer and hemorrhoid; the o-cymene-5-alcohol and triclosan have antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, Bacillus anthracis, Staphylococcus aureus, Streptococcus albus, etc., and tranexamic acid has effect in relieving hemorrhage symptoms. By the synergistic effect of the components and the other components in the formula, the emulsion disclosed by the invention can be coated on the anus to effectively prevent and treat hemorrhoids and reduce the pain of a patient.
2. The preparation method is simple and quick, and is convenient for batch and quick production.
3. The wet tissue is used for carrying the effective lotion, so that the effect of preventing and treating the hemorrhoids can be achieved by wiping the anus, and the use and the carrying are convenient.
Detailed Description
Hereinafter, embodiments of the present invention will be described in detail. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
Example 1
The emulsion for preventing and treating the hemorrhoids comprises the following components in percentage by weight:
3% of egg oil, 1.0% of polyglycerol-10 laurate, 0.1% of tocopherol acetate, 0.2% of o-cymene-5-ol, 0.2% of triclosan, 0.2% of butylated hydroxytoluene, 0.2% of borneol, 0.01% of musk ketone, 0.3% of xanthan gum, 5.0% of glycerol, 4.0% of glycerol glucoside, 2% of alum, 2% of zinc gluconate, 2% of tranexamic acid, 8.0% of hydrolyzed pearl liquid, 0.1% of EDTA disodium, 0.2% of phenoxyethanol, 0.1% of methylparaben, the balance of water, and,
The preparation method of the emulsion for preventing and treating hemorrhoids comprises the following steps:
s1, oil phase preparation: sequentially adding the egg oil, polyglycerol-10 lauric acid, tocopherol acetate, o-cymene-5-alcohol, triclosan, butylated hydroxytoluene, borneol and muscone into an oil phase pot, heating to 80-85 ℃, and uniformly stirring;
s2, preparing a water phase: adding xanthan gum, glycerol glucoside, Alumen, zinc gluconate, tranexamic acid, hydrolyzed Margarita liquid, phenoxyethanol, methyl hydroxybenzoate and water into water phase pot, heating to 80-85 deg.C, and stirring;
s3, emulsification: and (3) adding the raw materials in the water phase pot and the oil phase pot into an emulsifying pot, uniformly stirring, cooling to 40-45 ℃, filtering and discharging to obtain a finished product.
Preferably, in S3, the raw materials in the emulsifying pot are stirred uniformly, homogenized for 5 minutes, and then cooled.
A wet paper towel for preventing and treating hemorrhoid is prepared by soaking the folded non-woven fabric in the emulsion for preventing and treating hemorrhoid, filtering out the residual emulsion, bagging and sealing.
Example 2
The emulsion for preventing and treating the hemorrhoids comprises the following components in percentage by weight:
egg oil 5%, polyglycerol-10 laurate 0.8%, tocopherol acetate 0.5%, o-cymene-5-ol 0.1%, triclosan 0.1%, butylated hydroxytoluene 0.1%, borneol 0.3%, muscone 0.005%, xanthan gum 0.2%, glycerol 6%, glycerol glucoside 2%, alum 1.2%, zinc gluconate 1.5%, tranexamic acid 1%, hydrolyzed pearl liquid 5.0%, EDTA disodium 0.06%, phenoxyethanol 0.3%, methylparaben 0.2%, and the balance of water.
The preparation method of the emulsion for preventing and treating hemorrhoids comprises the following steps:
s1, oil phase preparation: sequentially adding the egg oil, polyglycerol-10 lauric acid, tocopherol acetate, o-cymene-5-alcohol, triclosan, butylated hydroxytoluene, borneol and muscone into an oil phase pot, heating to 80-85 ℃, and uniformly stirring;
s2, preparing a water phase: adding xanthan gum, glycerol glucoside, Alumen, zinc gluconate, tranexamic acid, hydrolyzed Margarita liquid, phenoxyethanol, methyl hydroxybenzoate and water into water phase pot, heating to 80-85 deg.C, and stirring;
s3, emulsification: and (3) adding the raw materials in the water phase pot and the oil phase pot into an emulsifying pot, uniformly stirring, cooling to 40-45 ℃, filtering and discharging to obtain a finished product.
Preferably, in S3, the raw materials in the emulsifying pot are stirred uniformly, homogenized for 5 minutes, and then cooled.
A wet paper towel for preventing and treating hemorrhoid is prepared by soaking the folded non-woven fabric in the emulsion for preventing and treating hemorrhoid, filtering out the residual emulsion, bagging and sealing.
Example 3
The emulsion for preventing and treating the hemorrhoids comprises the following components in percentage by weight:
egg oil 6%, polyglycerol-10 laurate 0.5%, tocopherol acetate 0.2, o-cymene-5-ol 0.1%, triclosan 0.15%, butylated hydroxytoluene 0.1%, borneol 0.1%, muscone 0.005%, xanthan gum 0.1%, glycerol 5.0%, glycerol glucoside 2%, alum 1%, zinc gluconate 0.2%, tranexamic acid 0.5%, hydrolyzed pearl liquid 3.0%, EDTA disodium 0.05%, phenoxyethanol 0.1%, methylparaben 0.1%, and water in balance.
The preparation method of the emulsion for preventing and treating hemorrhoids comprises the following steps:
s1, oil phase preparation: sequentially adding the egg oil, polyglycerol-10 lauric acid, tocopherol acetate, o-cymene-5-alcohol, triclosan, butylated hydroxytoluene, borneol and muscone into an oil phase pot, heating to 80-85 ℃, and uniformly stirring;
s2, preparing a water phase: adding xanthan gum, glycerol glucoside, Alumen, zinc gluconate, tranexamic acid, hydrolyzed Margarita liquid, phenoxyethanol, methyl hydroxybenzoate and water into water phase pot, heating to 80-85 deg.C, and stirring;
s3, emulsification: and (3) adding the raw materials in the water phase pot and the oil phase pot into an emulsifying pot, uniformly stirring, cooling to 40-45 ℃, filtering and discharging to obtain a finished product.
Preferably, in S3, the raw materials in the emulsifying pot are stirred uniformly, homogenized for 5 minutes, and then cooled.
A wet paper towel for preventing and treating hemorrhoid is prepared by soaking the folded non-woven fabric in the emulsion for preventing and treating hemorrhoid, filtering out the residual emulsion, bagging and sealing.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.

Claims (7)

1. The emulsion for preventing and treating hemorrhoids is characterized by comprising the following components in percentage by weight:
3 to 6 percent of egg oil, 0.5 to 1.0 percent of polyglycerol-10 laurate, 0.1 to 0.5 percent of tocopherol acetate, 0.05 to 0.2 percent of o-cymene-5-alcohol, 0.05 to 0.25 percent of triclosan, 0.1 to 0.2 percent of butylated hydroxytoluene, 0.1 to 0.5 percent of borneol, 0.001 to 0.01 percent of muscone, 0.1 to 0.3 percent of xanthan gum, 5.0 to 8.0 percent of glycerol, 1.0 to 4.0 percent of glycerol glucoside, 0.5 to 2.5 percent of alum, 0.5 to 2.5 percent of zinc gluconate, 0.5 to 2.5 percent of tranexamic acid, 3.0 to 8.0 percent of pearl hydrolysate, 0.02 to 0.1 percent of disodium EDTA, 0.1 to 0.4 percent of phenoxyethanol, 0.1 to 0.2 percent of methylparaben, and the balance of water.
2. The emulsion for preventing and treating hemorrhoids according to claim 1, wherein the components are preferably:
3% of egg oil, 1.0% of polyglycerol-10 laurate, 0.1% of tocopherol acetate, 0.2% of o-cymene-5-ol, 0.2% of triclosan, 0.2% of butylated hydroxytoluene, 0.2% of borneol, 0.01% of musk ketone, 0.3% of xanthan gum, 5.0% of glycerol, 4.0% of glycerol glucoside, 2% of alum, 2% of zinc gluconate, 2% of tranexamic acid, 8.0% of hydrolyzed pearl liquid, 0.1% of EDTA disodium, 0.2% of phenoxyethanol, 0.1% of methylparaben and the balance of water.
3. The emulsion for preventing and treating hemorrhoids according to claim 1, wherein the components are preferably:
5% of egg oil, 0.8% of polyglycerol-10 laurate, 0.5% of tocopherol acetate, 0.1% of o-cymene-5-alcohol, 0.1% of triclosan, 0.1% of butylated hydroxytoluene, 0.3% of borneol, 0.005% of musk ketone, 0.2% of xanthan gum, 6% of glycerol, 2% of glycerol glucoside, 1.2% of alum, 1.5% of zinc gluconate, 1% of tranexamic acid, 5.0% of hydrolyzed pearl liquid, 0.06% of EDTA disodium, 0.3% of phenoxyethanol, 0.2% of methylparaben and the balance of water.
4. The emulsion for preventing and treating hemorrhoids according to claim 1, wherein the components are preferably:
6% of egg oil, 0.5% of polyglycerol-10 laurate, 0.2% of tocopherol acetate, 0.1% of o-cymene-5-ol, 0.15% of triclosan, 0.1% of butylated hydroxytoluene, 0.1% of borneol, 0.005% of musk ketone, 0.1% of xanthan gum, 5.0% of glycerol, 2% of glycerol glucoside, 1% of alum, 0.2% of zinc gluconate, 0.5% of tranexamic acid, 3.0% of pearl hydrolysate, 0.05% of EDTA disodium, 0.1% of phenoxyethanol, 0.1% of methylparaben and the balance of water.
5. A process for the preparation of a hemorrhoid control emulsion according to any of claims 1 to 4, characterized in that it is carried out by the following steps:
s1, oil phase preparation: sequentially adding the egg oil, polyglycerol-10 lauric acid, tocopherol acetate, o-cymene-5-alcohol, triclosan, butylated hydroxytoluene, borneol and muscone into an oil phase pot, heating to 80-85 ℃, and uniformly stirring;
s2, preparing a water phase: adding xanthan gum, glycerol glucoside, Alumen, zinc gluconate, tranexamic acid, hydrolyzed Margarita liquid, phenoxyethanol, methyl hydroxybenzoate and water into water phase pot, heating to 80-85 deg.C, and stirring;
s3, emulsification: and (3) adding the raw materials in the water phase pot and the oil phase pot into an emulsifying pot, uniformly stirring, cooling to 40-45 ℃, filtering and discharging to obtain a finished product.
6. The method for preparing emulsion for preventing and treating hemorrhoids as claimed in any one of claims 1 to 4, wherein in S3, the raw materials in the emulsifying pot are stirred uniformly, homogenized for 5 minutes, and then cooled.
7. A hemorrhoid prevention wet tissue, characterized in that, the hemorrhoid prevention wet tissue is obtained by dry-soaking the folded non-woven fabric in the hemorrhoid prevention emulsion of any one of claims 1 to 4, filtering the excess emulsion, bagging and sealing.
CN202011165759.7A 2020-10-27 2020-10-27 Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids Pending CN112220816A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011165759.7A CN112220816A (en) 2020-10-27 2020-10-27 Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011165759.7A CN112220816A (en) 2020-10-27 2020-10-27 Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids

Publications (1)

Publication Number Publication Date
CN112220816A true CN112220816A (en) 2021-01-15

Family

ID=74109747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011165759.7A Pending CN112220816A (en) 2020-10-27 2020-10-27 Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids

Country Status (1)

Country Link
CN (1) CN112220816A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106890211A (en) * 2017-04-20 2017-06-27 陈贻范 A kind of hemorrhoid injection and preparation method thereof
CN107951836A (en) * 2017-12-27 2018-04-24 山东宏济堂制药集团股份有限公司 A kind of muskone suppository and its preparation method and application
CN108403939A (en) * 2018-04-25 2018-08-17 中国计量大学 Treat compound Chinese medicinal preparation and the Chinese medicine composition used of hemorrhoid and constipation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106890211A (en) * 2017-04-20 2017-06-27 陈贻范 A kind of hemorrhoid injection and preparation method thereof
CN107951836A (en) * 2017-12-27 2018-04-24 山东宏济堂制药集团股份有限公司 A kind of muskone suppository and its preparation method and application
CN108403939A (en) * 2018-04-25 2018-08-17 中国计量大学 Treat compound Chinese medicinal preparation and the Chinese medicine composition used of hemorrhoid and constipation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
吕兰薰等: "《常用中药药理》", 31 December 1979 *
谢秀琼: "《中药新制剂开发与应用 第2版》", 30 September 1994 *
陈菊: "坐浴Ⅰ号治疗痔瘘术后100例", 《浙江中医杂志》 *

Similar Documents

Publication Publication Date Title
CN108348577A (en) Sea-mussel mucin product and its application for inhibiting scytitis
JPH0739347B2 (en) Uses of sulfated sugars
AU762860B2 (en) Vitamin E and esters thereof for use in the topical treatment of mucosal pathologies
US4708873A (en) Method of chemically debriding uncerated necrotic tissue
US5925621A (en) Method for preventing sexually transmitted diseases
CN112220816A (en) Emulsion for preventing and treating haemorrhoids, preparation method thereof and wet tissue for preventing and treating haemorrhoids
EP1282429B1 (en) Pharmaceutical gel composition
CN1116885C (en) Medicine for treating piles
US20090247494A1 (en) Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders
US11883412B2 (en) Treatment for cellulitis and pre-operative treatment
RU2148989C1 (en) Preparation for treatment of sluggish wound and trophic ulcer (variants)
Fothergill A Clinical Lecture ON THE BAD HABIT OF VAGINAL DOUCHING: Given at the Manchester Royal Infirmary
CN111671726A (en) Composition for preventing postoperative infection of hemorrhoids and preparation method thereof
RU2214822C2 (en) Method for treating closed mechanic lesions of soft tissues and preventing surgical infection
Turner Salsalate. Anti-inflammatory/analgesic. After absorption is broken down to SALICYLIC ACID. Uses and adverse effects similar to ACETYLSALICYLIC ACID.
CN116077523A (en) Composition for preventing and treating hemorrhoids and preparation method and application thereof
CN103272042A (en) Smoked lotion for treating hemorrhoids and fistula
AU2001242100B2 (en) Pharmaceutical gel composition
JPH08104617A (en) Application of sulfated saccharide
Hajra et al. Thrombophlebitis of the Cavernous Sinus
Turner Selenium sulphide. Reduces formation of dandruff and other forms of eczema
Vaughn et al. A New Antibiotic Combination for Topical Use in Surgery: Preliminary Report
Weeks OPHTHALMIA NEONATORUM-ITS CAUSE, PREVENTION, AND TREATMENT
CN110507730A (en) A kind of Chinese medicine composition that treating hemorrhoid and Chinese materia medica preparation and its application
Byers Ruptured Tubal Pregnancy: Abdominal Section: Removal of Fœtus and Gestation Cyst: Recovery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210115